title: Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen.
abstract: BACKGROUND
  Recent studies showed that postmenopausal women lost less bone mass when supplemented with calcium or estrogen therapy. However, the safety of the treatments in terms of the risk of calcium oxalate stone formation is unknown. We therefore conducted this study to determine the alteration in calcium oxalate supersaturation after calcium supplement or after combined calcium and estrogen therapy in postmenopausal osteoporotic women.
  
  
  METHODS
  Fifty-six postmenopausal women were enrolled in this study. All subjects were more than 10 years postmenopausal with vertebral or femoral osteoporosis by bone mineral density criteria. They were randomly allocated to receive either 625 mg of calcium carbonate (250 mg of elemental calcium) at the end of a meal three times a day (group A, n=26) or calcium carbonate in the same manner plus 0.625 mg/day of conjugated equine estrogen and 5 mg medrogestone acetate from day 1-12 each month (group B, n=30). The age (mean +/- S.E.M.) was 66.3 +/- 1.2 and 65.1 +/- 1.1 years, weight 54.1 +/- 1.2 and 55.3 +/- 2.1 kg, in group A and group B, respectively. Urine specimens (24-h) were collected at baseline and 3 months after treatment for the determination of calcium oxalate saturation by using Tiselius's index (AP(CaOx)) and calcium/citrate ratio.
  
  
  RESULTS
  After 3 months of treatment, there was no significant alteration from baseline for urinary excretion of calcium, citrate and oxalate. Urinary phosphate excretion was significantly reduced (6.3 +/- 0.7 vs. 5.1 +/- 0.7 mmol/day for group A and 8.2 +/- 0.9 vs. 5.8 +/- 0.7 mmol/day for group B, P<0.05), whereas net alkaline absorption was significantly elevated (10.1 +/- 3.6 vs. 20.1 +/- 4.4 meq/day for group A and 4.8 +/- 3.2 vs. 19.9 +/- 3.6 meq/day for group B, P<0.05). Calcium/citrate ratio and AP(CaOx) determined at baseline were not different from the corresponding values after treatment in both groups; calcium/citrate: 10.1 +/- 3.1 vs. 10.1 +/- 2.5 for group A and 9.3 +/- 1.8 vs. 11.9 +/- 2.5 for group B and AP(CaOx): 1.1 +/- 0.1 vs. 1.3 +/- 0.2 for group A and 1.2 +/- 0.2 vs. 1.1 +/- 0.1 for group B. There were eight and nine patients with high AP(CaOx), or >2, at baseline and after treatment, respectively.
  
  
  CONCLUSIONS
  Calcium supplement with a meal or combined calcium supplement and estrogen therapy is not associated with a significant increased risk of calcium oxalate stone formation in the majority of postmenopausal osteoporotic patients. Determination of urinary saturation for calcium oxalate after calcium and estrogen supplements, especially at the initial phase of treatment, may be helpful in the avoidance of nephrolithiasis.
authors.affiliation: Department of Medicine, Ramathibodi Hospital, Mahidol University, Rama 6, Bangkok 10400, Thailand. rasdr@mahidol.ac.th
authors.forename: Somnuek
authors.initials: S
authors.lastname: Domrongkitchaiporn
authors.forename: Boonsong
authors.initials: B
authors.lastname: Ongphiphadhanakul
authors.forename: Wasana
authors.initials: W
authors.lastname: Stitchantrakul
authors.forename: Sirinthorn
authors.initials: S
authors.lastname: Chansirikarn
authors.forename: Gobchai
authors.initials: G
authors.lastname: Puavilai
authors.forename: Rajata
authors.initials: R
authors.lastname: Rajatanavin
mesh_terms: D000368:Aged; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000009:adverse effects*; D002129:Calcium Oxalate / Q000652:urine; D019587:Dietary Supplements; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced*; D008524:Medrogestone / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D018570:Risk Assessment
chemical_list: D004966:Estrogens, Conjugated (USP); D008524:Medrogestone; D002129:Calcium Oxalate; D002119:Calcium Carbonate